Third-Quarter Global Net Revenues from the Immunology Portfolio Were $9.165 Billion, an Increase of 16.3 Percent on a Reported Basis, or 16.6 Percent on an Operational Basis; Glob ...
Third quarter 2026 revenues increased 36% to $5.1 billion versus third quarter 2025Dupixent® global net sales(recorded by Sanofi) increased 35% ...
<?xml encoding="utf-8" ?> Regeneron Pharmaceuticals REGN reported third-quarter financial results on Friday. The transcript ...
Zacks Investment Research on MSN
GILD beats Q3 earnings on HIV strength & Trodelvy sales growth
Gilead Sciences GILD reported third-quarter 2026 adjusted earnings of $2.55 per share, up 3.2% year over year and beating the Zacks Consensus Estimate of $2.17. Adjusted earnings increased as higher ...
News about new cancer treatments is announced around the world almost every day.In this series, I search for information from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results